Mapp Biopharmaceutical, Inc.
San Diego, California, United States
Purpose
to fund proof of principle for the expression of CHO-derived ZMapp™ monoclonal antibodies to provide the basis for a CHO-based process to supply larger amounts of CHO-derived ZMapp™ drug product to Africa for early phase testing and compassionate use to those suffering from Ebola virus disease, thereby assisting in the control of the spread of this lethal disease
Division
Global Development
Date
February 2015
Region Served
GLOBAL
Committed amount
$440,169
Grant topic
Emergency Response
Duration (months)
7
Grantee location
San Diego, California, United States
Related work
More about our financials
Our story
Learn about the origins of the foundation and the values that drive our work.
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.